takeda - Search News

Ascentage, Takeda Pharmaceutical Company

Takeda-backed Ascentage Pharma sets terms for $170M IPO

Takeda-backed Ascentage Pharma Group (AAPG) (ASPHF), which is developing treatments for blood cancers, has set terms for a $170M U.S. initial public offering. Read more here.

Reuters · 6d

Takeda-backed Ascentage Pharma targets $1.8 bln valuation in US IPO

Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.

Bloomberg L.P. · 3d

Ascentage Pharma’s US Shares Climb After $126 Million IPO

Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s US trading debut, after pricing its $126.4 million initial public offering at a discount to its Asian stock.

Seeking Alpha on MSN · 3d

Takeda-backed Ascentage Pharma prices $126M U.S. IPO

Ascentage Pharma Group (AAPG) (AAPGV) (OTCPK:ASPHF), which is backed by Takeda (NYSE:TAK), has priced a $126M U.S. initial public offering. The China-based drug developer priced 7.33M shares at $17.25 per share,

Reuters on MSN · 3d

Takeda-backed Ascentage Pharma aims to raise $126 million in US IPO

Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.

FiercePharma2d

Takeda bids adieu to Uloric after gout med's gradual fade from glory

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some safety setbacks and years of generic competition, Takeda is calling it quits ...

Zawya8h

Takeda and King Saud University Medical City forge strategic partnership to advance healthcare training in Saudi Arabia

Riyadh, The Kingdom of Saudi Arabia: Takeda, the global biopharmaceutical company, is pleased to announce a new strategic ...

FierceBiotech5d

Takeda tightens reins on early-stage investments, looks to expand option deals: R&D head

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...

FiercePharma11d

JPM25: Takeda spotlights 6 pipeline assets that could pull down up to $20B in collective peak sales

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

Atomi Financial Group Inc. Sells 5,942 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Atomi Financial Group Inc. trimmed its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) ...

Crews building new Takeda tower in Cambridge celebrate a milestone, in frigid temps

More than 250 people — a mix of construction crew members, community and business leaders, and Takeda employees — braved ...

Gaming Legends on MSN4d

Mortal Kombat X #31 Takeda VS. The Fatal Eight (Read & Review)

SUBSCRIBE! Never Miss A Video: <a href=" to read the issue for yourself with all the text? Click right here to buy the issue ...

Takeda Recognized as a Top Employer in Canada for Third Consecutive Year

Takeda Canada Inc. ("Takeda") announced that, for the third consecutive year, it has received Top Employer® certification for ...

GlobalData on MSN6d

Health Canada gives Takeda’s mCRC capsules market authorisation

Health Canada has granted market authorisation to Takeda Canada for FRUZAQLA (fruquintinib) capsules to treat adults with ...

pharmaphorum5d

Takeda backs biomarker trial for Crohn's prevention

The INTERCEPT study is being funded to the tune of €38 million (nearly $40 million) over the next five years and is described ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Ascentage, Takeda Pharmaceutical Company

Related topics